首页> 外文期刊>Journal of neurosurgical sciences >The neurosurgical management of prolactinomas.
【24h】

The neurosurgical management of prolactinomas.

机译:泌乳素瘤的神经外科治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The objective was to discuss the neurosurgical management of the prolactinomas. METHODS: Five-hundred-fifty patients suffering from prolactinoma were treated with trans-sphenoidal and transcranial approach. The diagnosis of prolactinoma was based on various degree of high level prolactinemia, galactorrhea, gonodal disturbance, neurological examination and radiological findings. In all cases the adenoma was histologically verified. The patients were investigated according to the anatomo-radiological classification of Hardy and Vesina, and the range of preoperative PRL basal levels. RESULTS: Follow-up was ascertained in 81% of patients who were followed for a mean of 7.2 year (1-10 year). While the total removal percentage was 98% in the group with microprolactinoma, this ratio dropped to 63.9% for macroadenomas and 23.5% for giant adenomas. Early improvement of prolactin level ratio was 81.6% in microprolactinomas, 28.3 in macroadenomas and 11.7% in giant adenomas. Hormonal cure was 64.3% in microadenomas, 6.7% in macroadenomas and 0% in giant adenomas. The ratio of hormonal cure was decreasing in patients with high prolactin levels. In the follow-up recurrence of prolactinomas occurred in 39% of the patients. CONCLUSIONS: Medical treatment is the first step in prolactin secreting adenomas. Trans-sphenoidal microsurgery became popular in treatment of prolactinomas because of low operative morbidity and mortality. Patients with recurrence should be evaluated for second step treatment (surgery, bromocriptine, or radiotherapy).
机译:背景:目的是讨论泌乳素瘤的神经外科治疗。方法:对550例泌乳素瘤患者进行经蝶窦和经颅入路治疗。泌乳素瘤的诊断基于各种程度的高水平泌乳素血症,溢乳,淋病,神经系统检查和影像学发现。在所有情况下,腺瘤均经过组织学证实。根据Hardy和Vesina的解剖放射学分类以及术前PRL基础水平的范围对患者进行了调查。结果:确定随访的患者中平均81年的7.2年(1-10年)。尽管微泌乳素瘤组的总清除率为98%,但对于大腺瘤,该比率下降至63.9%,对于巨腺瘤,该比率下降至23.5%。微泌乳素瘤的催乳素水平比率的早期改善为81.6%,大腺瘤为28.3,巨腺瘤为11.7%。激素治疗在微腺瘤中为64.3%,在大腺瘤中为6.7%,在巨大腺瘤中为0%。催乳素水平高的患者激素治愈率正在下降。在随访中,泌乳素瘤的复发发生在39%的患者中。结论:药物治疗是催乳素分泌腺瘤的第一步。经蝶窦显微手术因其手术发病率和死亡率低而在催乳素瘤的治疗中变得很流行。复发患者应接受第二步治疗(手术,溴隐亭或放疗)评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号